UNSPSC 51391806: Pholedrine

This classification denotes an adrenergic agent with the molecular formula C10H15NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier AY28O44JGD, chemically known as p-hydroxy-n,alpha-dimethylphenethylamine but generally known as pholedrine, which bears US NIH Compound Identifier 4655. European Medicines Agency schedules Pholedrine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09796MIG. The term PHOLEDRINE is an International Non-Proprietary Name.

UNSPSC 51391806 Pholedrine is a Commodity code that covers pharmaceutical products and related medical supplies procured by state and local health agencies. Recent state and local activity under this code reflects procurement of opioid-antagonist medications and drug-management systems to support community health and emergency response initiatives. Seminole County, Florida, for example, solicited naloxone and safe drug deactivation systems through an IFB (Invitation for Bid) process, procuring 1,900 units of naloxone and 800 deactivation systems annually with quarterly delivery to the county community health building. The Texas Health and Human Services Commission issued a Request for Information to explore direct-to-manufacturer prescription programs and vendor capabilities for self-insured pharmacy benefit arrangements. Issuing bodies under this code include county health departments and state health and human services agencies responsible for pharmaceutical procurement, emergency medical supplies, and pharmacy benefit management.

Geographic activity centers on Florida and Texas based on recent solicitations, with Seminole County, Florida and the Texas HHS Commission representing the documented recent procurement activity. Seminole County's IFB, posted June 30, 2026 (with a due date of July 26, 2023 per the source), required competitive bids for naloxone and drug deactivation systems with quarterly deliveries, fixed pricing on a line-item basis, and standard vendor compliance requirements including E-Verify, drug-free workplace certification, and insurance coverage. The Texas HHS RFI, issued April 3, 2026, functioned as a preliminary market-intelligence gathering mechanism rather than a formal competitive solicitation, seeking vendor information on direct contracting capacity, negotiated net pricing models, and outcomes-based agreement capability before issuing a formal RFP. Neither procurement specified set-aside or disadvantaged-enterprise designations.